300 related articles for article (PubMed ID: 35304711)
1. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
[TBL] [Abstract][Full Text] [Related]
2. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Yang X; Li Y; Ren XT; Fan L; Hua B
World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
[TBL] [Abstract][Full Text] [Related]
4. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
6. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
[TBL] [Abstract][Full Text] [Related]
7. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
8. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
10. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
[TBL] [Abstract][Full Text] [Related]
11. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
[TBL] [Abstract][Full Text] [Related]
12. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
[TBL] [Abstract][Full Text] [Related]
14. Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.
Laws A; Dillon K; Kelly BN; Kantor O; Hughes KS; Gadd MA; Smith BL; Lamb LR; Specht M
Ann Surg Oncol; 2020 Nov; 27(12):4819-4827. PubMed ID: 32740737
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
[TBL] [Abstract][Full Text] [Related]
16. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy.
Tasdoven I; Balbaloglu H; Erdemir RU; Bahadir B; Guldeniz Karadeniz C
Medicine (Baltimore); 2022 Dec; 101(52):e32545. PubMed ID: 36596061
[TBL] [Abstract][Full Text] [Related]
17. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
18. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
[TBL] [Abstract][Full Text] [Related]
19. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
20. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.
Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L
Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
